GlassScriptPhysician profile
Thomas Michael Adams
NPI 1720069479
$6,080.08
in general payments reported to CMS, 2019-2025
42 companies · $894 in 2025
The $894 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,708 · 2020: $275 · 2021: $357 · 2022: $580 · 2023: $876 · 2024: $1,391 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,161.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $952.57 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $928.27 | 2019-2025 | Repatha, Otezla, Prolia |
| Abbvie INC. | $849.24 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $492.66 | 2019-2025 | Kisunla, Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $319.55 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $256.29 | 2021-2025 | |
| Pfizer INC. | $228.61 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $216.13 | 2019 | |
| Lundbeck LLC | $188.15 | 2022-2025 | Rexulti, Vyepti |
| Ironshore Pharmaceuticals INC. | $181.04 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $166.94 | 2022-2025 | |
| Allergan, INC. | $137.67 | 2019 | |
| Angiodynamics, INC. | $114.98 | 2023 | Auryon Laser System 100-120 Vac |
| Novo Nordisk INC | $97.79 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Supernus Pharmaceuticals, INC. | $88.59 | 2019-2024 | Qelbree |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $70.34 | 2024-2025 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.69 | 2019-2025 | Jardiance |
| Dexcom, INC. | $56.39 | 2022-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $51.40 | 2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $48.36 | 2019 | |
| Baxter Healthcare | $46.52 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Glaxosmithkline, LLC. | $45.56 | 2019-2025 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $41.65 | 2024-2025 | Auvelity |
| Ultragenyx Pharmaceutical INC. | $41.34 | 2024 | Crysvita |
| Phathom Pharmaceuticals, INC. | $39.27 | 2024-2025 | Voquezna |
| Genentech USA, INC. | $38.74 | 2019 | |
| Hologic Sales and Service, LLC | $30.93 | 2022-2025 | Aptima |
| Stryker Corporation | $28.99 | 2025 | Clottriever Bold Catheter |
| Shire North American Group INC | $28.05 | 2019 | |
| Boston Scientific Corporation | $25.22 | 2025 | Bodyguardian |
| Vanda Pharmaceuticals INC. | $24.99 | 2024 | Fanapt |
| Si-Bone, INC. | $22.26 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.87 | 2019 | |
| Kyowa Kirin, INC. | $20.29 | 2025 | |
| Philips North America LLC | $17.58 | 2024 | (Ck4) Mcot |
| Tris Pharma INC | $17.15 | 2025 | Onyda Xr |
| Collegium Pharmaceutical, INC. | $16.62 | 2024 | Belbuca |
| Inspire Medical Systems, INC. | $16.46 | 2024 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.65 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $14.59 | 2023 | Rexulti |
| Tonix Medicines, INC. | $14.04 | 2025 | Tonmya |
| Amarin Pharma, INC. | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.